TY - JOUR
T1 - Patent Foramen Ovale in Cryptogenic Stroke
T2 - Current Understanding and Management Options
AU - Wu, Lambert A.
AU - Malouf, Joseph F.
AU - Dearani, Joseph A.
AU - Hagler, Donald J.
AU - Reeder, Guy S.
AU - Petty, George W.
AU - Khandheria, Bijoy K.
PY - 2004/5/10
Y1 - 2004/5/10
N2 - There is increasing interest in the association between patent foramen ovale (PFO) and documented stroke of unknown cause, commonly referred to as cryptogenic stroke. We reviewed the literature and, on the basis of the available data, designed a diagnostic and treatment algorithm for patients with PFO and cryptogenic stroke. Patent foramen ovale is relatively common in the general population, but its prevalence is higher in patients with cryptogenic stroke. Importantly, paradoxical embolism through a PFO should be strongly considered in young patients with cryptogenic stroke. There is no consensus on the optimal management strategy, but treatment options include antiplatelet agents, warfarin sodium, percutaneous device closure, and surgical closure. High-risk features in the patient's history (ie, temporal association between Valsalva-inducing maneuvers and stroke, coexisting hypercoagulable state, recurrent strokes, and PFO with large opening, large right-to-left shunt, or right-to-left shunting at rest, and a coexisting atrial septal aneurysm) should prompt PFO closure.
AB - There is increasing interest in the association between patent foramen ovale (PFO) and documented stroke of unknown cause, commonly referred to as cryptogenic stroke. We reviewed the literature and, on the basis of the available data, designed a diagnostic and treatment algorithm for patients with PFO and cryptogenic stroke. Patent foramen ovale is relatively common in the general population, but its prevalence is higher in patients with cryptogenic stroke. Importantly, paradoxical embolism through a PFO should be strongly considered in young patients with cryptogenic stroke. There is no consensus on the optimal management strategy, but treatment options include antiplatelet agents, warfarin sodium, percutaneous device closure, and surgical closure. High-risk features in the patient's history (ie, temporal association between Valsalva-inducing maneuvers and stroke, coexisting hypercoagulable state, recurrent strokes, and PFO with large opening, large right-to-left shunt, or right-to-left shunting at rest, and a coexisting atrial septal aneurysm) should prompt PFO closure.
UR - http://www.scopus.com/inward/record.url?scp=2342516160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342516160&partnerID=8YFLogxK
U2 - 10.1001/archinte.164.9.950
DO - 10.1001/archinte.164.9.950
M3 - Review article
C2 - 15136302
AN - SCOPUS:2342516160
SN - 0003-9926
VL - 164
SP - 950
EP - 956
JO - Archives of internal medicine
JF - Archives of internal medicine
IS - 9
ER -